tadekinig alfa

Home
Ligands
tadekinig alfa

GtoPdb Ligand ID: 10077

Compound class: Peptide or derivative

Comment: Tadekinig alfa is recombinant IL-18-binding protein in its mature form without the 30 amino acid signal peptide of the precursor protein (NP_001034748). It is being developed by AB2Bio.

Summary
Biological activity
Clinical data
References
Structure
Immunopharmacology

References
1. Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA et al.. (2018) Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. Ann Rheum Dis, 77 (6): 840-847. [PMID:29472362]
2. Yasin S, Schulert GS. (2018) Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment. Curr Opin Rheumatol, 30 (5): 514-520. [PMID:29870499]

References

1. Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA et al.. (2018)
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
Ann Rheum Dis, 77 (6): 840-847. [PMID:29472362]

2. Yasin S, Schulert GS. (2018)
Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment.
Curr Opin Rheumatol, 30 (5): 514-520. [PMID:29870499]